AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
AAPL   325.12 (+0.55%)
MSFT   185.36 (+0.24%)
FB   230.16 (-1.10%)
GOOGL   1,439.25 (-0.21%)
AMZN   2,478.40 (+0.24%)
NVDA   350.78 (-0.63%)
CGC   16.57 (+2.66%)
BABA   218.61 (+2.00%)
MU   48.92 (+4.49%)
GE   7.36 (+4.40%)
TSLA   882.96 (+0.16%)
AMD   52.73 (-1.51%)
T   31.51 (+1.68%)
ACB   14.30 (-1.58%)
F   6.19 (+4.92%)
GILD   74.40 (+1.56%)
DIS   122.18 (+2.89%)
NFLX   421.97 (-1.25%)
BAC   25.99 (+4.63%)
BA   173.16 (+12.95%)
Log in

NASDAQ:ACRXAcelRx Pharmaceuticals Stock Price, Forecast & News

$1.29
-0.03 (-2.27 %)
(As of 06/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.26
Now: $1.29
$1.34
50-Day Range
$1.28
MA: $1.46
$1.69
52-Week Range
$0.70
Now: $1.29
$3.02
Volume1.25 million shs
Average Volume1.02 million shs
Market Capitalization$104.19 million
P/E RatioN/A
Dividend YieldN/A
Beta1.76
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Read More
AcelRx Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACRX
CUSIPN/A
Phone650-216-3500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.29 million
Book Value($0.52) per share

Profitability

Net Income$-53,240,000.00
Net Margins-2,302.53%

Miscellaneous

Employees61
Market Cap$104.19 million
Next Earnings Date8/3/2020 (Estimated)
OptionableOptionable

Receive ACRX News and Ratings via Email

Sign-up to receive the latest news and ratings for ACRX and its competitors with MarketBeat's FREE daily newsletter.

AcelRx Pharmaceuticals (NASDAQ:ACRX) Frequently Asked Questions

How has AcelRx Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

AcelRx Pharmaceuticals' stock was trading at $1.22 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ACRX shares have increased by 5.7% and is now trading at $1.29. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of AcelRx Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AcelRx Pharmaceuticals in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for AcelRx Pharmaceuticals.

When is AcelRx Pharmaceuticals' next earnings date?

AcelRx Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for AcelRx Pharmaceuticals.

How were AcelRx Pharmaceuticals' earnings last quarter?

AcelRx Pharmaceuticals Inc (NASDAQ:ACRX) issued its earnings results on Monday, May, 11th. The specialty pharmaceutical company reported ($0.20) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.03. The specialty pharmaceutical company earned $0.39 million during the quarter, compared to analysts' expectations of $2.65 million. View AcelRx Pharmaceuticals' earnings history.

What price target have analysts set for ACRX?

3 analysts have issued 12 month price targets for AcelRx Pharmaceuticals' stock. Their forecasts range from $2.00 to $8.00. On average, they anticipate AcelRx Pharmaceuticals' share price to reach $5.67 in the next twelve months. This suggests a possible upside of 339.3% from the stock's current price. View analysts' price targets for AcelRx Pharmaceuticals.

Has AcelRx Pharmaceuticals been receiving favorable news coverage?

Press coverage about ACRX stock has trended very negative this week, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. AcelRx Pharmaceuticals earned a media sentiment score of -3.1 on InfoTrie's scale. They also gave news stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the next few days. View the latest news aboutAcelRx Pharmaceuticals.

Who are some of AcelRx Pharmaceuticals' key competitors?

What other stocks do shareholders of AcelRx Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AcelRx Pharmaceuticals investors own include Advanced Micro Devices (AMD), Amarin (AMRN), Amicus Therapeutics (FOLD), Novavax (NVAX), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO), Agile Therapeutics (AGRX), Cyberark Software (CYBR), Fitbit (FIT) and Flexion Therapeutics (FLXN).

Who are AcelRx Pharmaceuticals' key executives?

AcelRx Pharmaceuticals' management team includes the following people:
  • Mr. Vincent J. Angotti, CEO & Director (Age 51)
  • Dr. Pamela Pierce Palmer, Co-Founder, Chief Medical Officer & Director (Age 56)
  • Mr. Raffi Mark Asadorian, Chief Financial Officer (Age 50)
  • Mr. Lawrence G. Hamel, Chief Devel. Officer (Age 67)
  • Mr. Anil N. Dasu, Chief Engineering Officer (Age 56)

What is AcelRx Pharmaceuticals' stock symbol?

AcelRx Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACRX."

Who are AcelRx Pharmaceuticals' major shareholders?

AcelRx Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (7.04%), State Street Corp (1.77%), Geode Capital Management LLC (1.43%), Morgan Stanley (0.37%), Bank of New York Mellon Corp (0.29%) and Wells Fargo & Company MN (0.27%). Company insiders that own AcelRx Pharmaceuticals stock include Badri N Dasu, Lawrence G Hamel, Mark G Edwards, Pamela P Palmer, Raffi Asadorian and Vincent J Angotti. View institutional ownership trends for AcelRx Pharmaceuticals.

Which institutional investors are selling AcelRx Pharmaceuticals stock?

ACRX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, UBS Group AG, Lincoln Capital Corp, and Bank of New York Mellon Corp. View insider buying and selling activity for AcelRx Pharmaceuticals.

Which institutional investors are buying AcelRx Pharmaceuticals stock?

ACRX stock was bought by a variety of institutional investors in the last quarter, including Robertson Stephens Wealth Management LLC, Geode Capital Management LLC, BlackRock Inc., Wells Fargo & Company MN, State Street Corp, SG Americas Securities LLC, Meeder Asset Management Inc., and Alliancebernstein L.P.. Company insiders that have bought AcelRx Pharmaceuticals stock in the last two years include Mark G Edwards, Pamela P Palmer, Raffi Asadorian, and Vincent J Angotti. View insider buying and selling activity for AcelRx Pharmaceuticals.

How do I buy shares of AcelRx Pharmaceuticals?

Shares of ACRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AcelRx Pharmaceuticals' stock price today?

One share of ACRX stock can currently be purchased for approximately $1.29.

How big of a company is AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals has a market capitalization of $104.19 million and generates $2.29 million in revenue each year. The specialty pharmaceutical company earns $-53,240,000.00 in net income (profit) each year or ($0.67) on an earnings per share basis. AcelRx Pharmaceuticals employs 61 workers across the globe.

What is AcelRx Pharmaceuticals' official website?

The official website for AcelRx Pharmaceuticals is www.acelrx.com.

How can I contact AcelRx Pharmaceuticals?

AcelRx Pharmaceuticals' mailing address is 351 GALVESTON DRIVE, REDWOOD CITY CA, 94063. The specialty pharmaceutical company can be reached via phone at 650-216-3500 or via email at [email protected]

This page was last updated on 6/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.